CHAMPIONS ONCOLOGY, INC.
Financial highlights
| Metric | FY 04/30/25 | FY 04/30/24 | FY 04/30/23 | FY 04/30/22 | FY 04/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $56.9M | $50.2M | $53.9M | $49.1M | $41.0M |
| Cost of revenue | $28.4M | $29.4M | $29.5M | $23.6M | $21.4M |
| Research and development | $6.8M | $9.5M | $11.5M | $9.4M | $7.2M |
| Operating income | $4.6M | -$7.4M | -$5.3M | $607,000 | $366,000 |
| Pretax income | $4.6M | -$7.3M | -$5.3M | $583,000 | $437,000 |
| Income tax expense | -$75,000 | -$32,000 | $68,000 | $35,000 | $75,000 |
| Net income | $4.7M | -$7.3M | -$5.3M | $548,000 | $362,000 |
| Balance Sheet | |||||
| Current assets | $22.4M | $13.6M | $19.5M | $19.7M | $12.6M |
| Total assets | $32.3M | $26.1M | $34.3M | $35.4M | $27.6M |
| Current liabilities | $23.9M | $21.5M | $21.7M | $17.5M | $11.2M |
| Total liabilities | $28.6M | $28.0M | $29.7M | $26.3M | $20.2M |
| Stockholders' equity | $3.8M | -$1.9M | $4.6M | $9.1M | $7.4M |
| Cash Flow Statement | |||||
| Cash from operations | $7.4M | -$6.1M | $4.0M | $6.5M | -$1.7M |
| Depreciation and amortization | $1.6M | $1.9M | $2.1M | $1.5M | $925,000 |
| Stock-based compensation | $654,000 | $1.1M | $864,000 | $912,000 | $598,000 |
| Capital expenditure | $389,000 | $836,000 | $2.9M | $2.4M | $3.3M |
| Free cash flow | $7.0M | -$7.0M | $1.1M | $4.1M | -$5.0M |
| Share repurchases | $0 | $634,000 | $74,000 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 13.9M · Free float 53.3%
Annual filing data through FY ended April 30, 2025; float as of July 8, 2026.